Acapatamab

{
  "id": "MLC-T-ONC-009594",
  "term": "Acapatamab",
  "field": "Oncology and biomedicine",
  "definition": "A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration acapatamab binds to both CD3 on cytotoxic T lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.",
  "synonyms": [
    "HLE-BiTE AMG 160",
    "BITE AMG 160",
    "anti-PSMA/CD3 bispecific T-cell engager antibody AMG 160",
    "bispecific T-cell engager antibody AMG 160",
    "half-life extended bispecific T-cell engager antibody AMG 160",
    "anti-PSMA/CD3 BiTE antibody AMG 160"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/acapatamab/"
}